PacBio Announces A New Sequencer: PacBio Sequel

Sequel: PacBio's New Sequencing System

Sequel: PacBio’s New Sequencing System

In case you missed it, Last week, PacBio – the leader in long-read sequencing technology, announced that it is launching a new sequencer Sequel.  Announcing the Sequel, just a few days before the start of this year’s ASHG conference at Baltimore, PacBio said it will showcase Sequel at the 2015 ASHG meeting. The Sequel system is expected to be shipped to limited customers, including Roche for its assay development program, during the 4th quarter of 2015.  Shipments outside the U.S. are expected to commence thereafter.

In the press release announcing the Sequel, PacBio said

The Sequel System has been developed as part of the company’s collaboration with F. Hoffman-La Roche Ltd(Roche) to ultimately provide a nucleic acid sequencing system for use in human in vitro diagnostics.

Under the Roche-PacBio agreement, Roche will be paying $40M  for the development of Sequel. Roche has already paid $20M and the remaining 20M is expected by the fourth quarter of 2015.

The Sequel vs PacBio RS II

The new sequencer Sequel is powered by PacBio’s redesigned SMRT cells, which contains one million zero-mode waveguides during the launch.  In comparison to PacBio RS II system, The Sequel is a smaller machine with higher throughput.  The new sequencer, Sequel is less than one-third the size and weight, when compared with PacBio RS II. And the Sequel has 1M ZMW, in comparison 150,000 ZMWs in the PacBio RS II system. Therefore, the through-put of the Sequel is 7 times more reads than PacBio RS II.  The list price for the PacBio’s Sequel System in US is $350,000, in comparison to ~$750,000 for PacBio RS II.

With Sequel, one can get 10X coverage human data good enough to look at structural variants approximately about $3,000. For sequencing a human genome at 30X coverage, approximate cost is expected to be just around $10,000, in comparison to 20-25k using PacBio RS II.

The announcement of Sequel has been received very positively and has put PacBio in a strong position. The street reacted sharply with a spike in PacBio’s stocks and a drop in Illumina’s stock.

Sequel Effect: Pacbio, llumina Stock

Sequel Effect: Pacbio, llumina Stock

Here is the link-round up of blogs and press covering the launch of Sequel.

  1. PacBio Press Release: Pacific Biosciences Launches New Sequencing Platform Based on Its SMRT Technology
  2. PacBio Blog: Introducing the Sequel System: The Scalable Platform for SMRT Sequencing
  3. GenomeWeb: PacBio Launches Higher-Throughput, Lower-Cost Single-Molecule Sequencing System
  4. Bio IT: PacBio Announces Sequel Sequencing System
  5. Bio IT: A Worthy Sequel: PacBio’s New Sequencing System
  6. Bio Mick Watson: What does the PacBio Sequel mean for the future of sequencing?
  7. Core genomics: The new Pacific Biosciences sequencer
  8. Keith Robinson OmicsOmics Blog: PacBio Sequel: Smaller Box, Bigger Bang
  9. Mark ChaissonWhat does SEQUEL mean for human genetics?

PacBio Sequel Introduction Video

PacBio Sequel on NBC TV

Speak Your Mind

*